D'Almeida Kayigan W, Lert France, Spire Bruno, Dray-Spira Rosemary
Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136) - Équipe de recherche en épidémiologie sociale, Paris, France.
Centre de recherche en Epidemiologie et Sante des Populations Ringgold standard institution, Villejuif, Île-de-France, France.
Antivir Ther. 2016;21(8):661-670. doi: 10.3851/IMP3064. Epub 2016 Jun 29.
Disparities in combined antiretroviral therapy (cART) outcomes have been consistently reported among people living with HIV (PLWHIV). The present study aims at investigating the mechanisms underlying those disparities among PLWHIV in France.
We used data from the Vespa2 survey, a large national cross-sectional survey, representative of HIV-infected people followed at hospitals in 2011. Among participants diagnosed ≥1996, HIV treatment-naive at the time of cART initiation and on cART for at least 12 months, the frequency of sustained virological suppression (SVS; undetectable viral load [<50 copies/ml] for at least 6 months) at the time of the survey, was assessed and its social determinants were measured through logistic regression, accounting for clinical and biological determinants of response to cART.
Among 1,246 participants, 77.7% had achieved SVS. SVS was less frequent among those unemployed (0.6 [range 0.3-1.0]) and those with the lowest level of education (0.4 [range 0.2-0.9]). The late presenters, diagnosed at a CD4 T-cell count <200/mm (0.5 [range 0.3-0.9]) and the late starters, diagnosed at a CD4 T-cell count >200 but initiating cART at CD4 T-cell count <200 (0.3 [range 0.1-0.8]) were less likely than the ideal starters (≥350 CD4 T-cells/mm at cART initiation) to achieve SVS, as were those who reported suboptimal adherence versus those reporting optimal adherence (0.4 [range 0.2-0.7]). In bivariate analyses, material deprivation, discrimination and a weak social network were also associated with a poorer treatment response.
Structural social factors remain strong determinants of treatment response and should be addressed in a broad approach of care, but wider political issues should also be investigated.
抗逆转录病毒联合疗法(cART)治疗效果的差异在艾滋病毒感染者(PLWHIV)中一直有报道。本研究旨在调查法国艾滋病毒感染者中这些差异背后的机制。
我们使用了Vespa2调查的数据,这是一项大型的全国性横断面调查,代表了2011年在医院接受随访的艾滋病毒感染者。在1996年及以后被诊断、开始接受cART时未接受过艾滋病毒治疗且接受cART至少12个月的参与者中,评估了调查时持续病毒学抑制(SVS;病毒载量低于检测下限[<50拷贝/ml]至少6个月)的频率,并通过逻辑回归分析其社会决定因素,同时考虑了对cART反应的临床和生物学决定因素。
在1246名参与者中,77.7%实现了SVS。在失业者(0.6[范围0.3 - 1.0])和教育水平最低者(0.4[范围0.2 - 0.9])中,SVS的发生率较低。与理想启动者(cART启动时CD4 T细胞计数≥350个/mm³)相比,CD4 T细胞计数<200/mm³时被诊断的晚期就诊者(0.5[范围0.3 - 0.9])以及CD4 T细胞计数>200但在CD4 T细胞计数<200时开始接受cART的晚期启动者(0.3[范围0.1 - 0.8])实现SVS的可能性较小,报告依从性欠佳者与报告依从性良好者相比也是如此(0.4[范围0.2 - 0.7])。在双变量分析中,物质匮乏、歧视和薄弱的社会网络也与较差的治疗反应相关。
结构性社会因素仍然是治疗反应的重要决定因素,应在广泛的护理方法中加以解决,但更广泛的政治问题也应进行调查。